GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MYPHY) » Definitions » Median PS Value

Mayne Pharma Group (Mayne Pharma Group) Median PS Value : $0.00 (As of May. 21, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Mayne Pharma Group Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Mayne Pharma Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $21.469. Mayne Pharma Group's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-05-21), Mayne Pharma Group's share price is $0.00. Mayne Pharma Group's Median PS Value is $0.00. Therefore, Mayne Pharma Group's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Mayne Pharma Group's Median PS Value or its related term are showing as below:

During the past 13 years, the highest Price to Median PS Value of Mayne Pharma Group was 1.06. The lowest was 0.51. And the median was 0.62.

MYPHY's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.85
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Mayne Pharma Group Median PS Value Historical Data

The historical data trend for Mayne Pharma Group's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Median PS Value Chart

Mayne Pharma Group Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mayne Pharma Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mayne Pharma Group's Median PS Value

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Price-to-Median-PS-Value falls into.



Mayne Pharma Group Median PS Value Calculation

Mayne Pharma Group's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=21.469*0
=0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mayne Pharma Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $21.469.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mayne Pharma Group  (OTCPK:MYPHY) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Mayne Pharma Group's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.00/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mayne Pharma Group Median PS Value Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Mayne Pharma Group (Mayne Pharma Group) Business Description

Traded in Other Exchanges
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.